Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
4.960
+0.190 (3.98%)
At close: Sep 22, 2026, 4:00 PM EDT
4.990
+0.030 (0.60%)
After-hours: Sep 22, 2026, 7:39 PM EDT
Unicycive Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
138.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 675.00K | -276.00K | -29.02% |
| Dec 31, 2022 | 951.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| Caribou Biosciences | 10.04M |
| NRx Pharmaceuticals | 3.39M |
| Milestone Pharmaceuticals | 2.34M |
| MediciNova | 920.48K |
| Spruce Biosciences | 697.00K |
| Inovio Pharmaceuticals | 65.34K |
UNCY News
- 7 days ago - Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies - Newsfile Corp
- 7 days ago - Unicycive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 13 days ago - Unicycive Therapeutics Slides: Corporate presentation - Filings
- 21 days ago - Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics price target raised to $15 from $13 at Benchmark - TheFly
- 5 weeks ago - Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c) - TheFly
- 5 weeks ago - Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley - TheFly
- 5 weeks ago - Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim - TheFly